The purpose of this study is to test the safety of a measles, mumps, and rubella study vaccine made from a new measles stock seed (a component of the vaccine made in 2003) with rHA (recombinant human albumin).

Ages Eligible for Study:  12 Months   -   18 Months,  Genders Eligible for Study:  Both

Accepts Healthy Volunteers

Criteria

Inclusion Criteria:

• Healthy children 12 to 18 months of age.

Exclusion Criteria:

• Previous receipt of measles, mumps, rubella and/or varicella vaccine.
• Prior infection or exposure to (within last 4 weeks) measles, mumps, rubella, varicella and/or zoster.
• Any medical condition that might interfere with the immune response to the given vaccines (including HIV infection and/or cancer) or has undergone immunosuppressive (weakens your body’s ability to fight infection) therapy.
• History of seizures (convulsions)
• Allergies to any component of the vaccine, including sorbitol, gelatin, or neomycin.
• A recent (within the last 3 days) illness resulting in a fever (underarm temperature greater than 99.5° F [37.5° C]).